Skip to main content

Table 4 The Committee’s and the sample ranking of technologies accepted by the 2006/7 Basket Committee (monthly cost threshold = 125 NIS)

From: Do the equity-efficiency preferences of the Israeli Basket Committee match those of Israeli health policy makers?

Technology Rank Basket Committee Diagonal Rank survey - Total Rank survey - Physicians Rank survey - Members of the Basket Committee Rank efficiencya
Crestor Ezetrol 1 1 12 12 10 9
Atacand Ocsaar Diovan Olmetec 2 2 15 15 15 2
Lantus Levemir 3 3 15 15 15 4
Apidra Humalog Novorapid 4 4 15 15 15 7
Eloxatin 5 5 10 10 10 3
Xeloda 6 6 10 10 10 1
Herceptin 7 7 8 8 9 15
Hepsera 8 8 3 3 3 12
Viread 9 9 7 6 7 14
Prevnar 10 10 18 18 18 18
Mabthera 11 11 1 1 1 11
Keppra 12 12 13 13 14 5
Zyprexa 13 13 14 14 13 17
Exjade 14 14 5 4 4 13
Plavix (cardiac) 15 15 6 6 5 8
Growth hormon 16 16 9 9 8 10
Plavix (stroke) 17 17 1 1 1 6
Velcade 18 18 4 5 5 16
  1. aBy international data on cost per QALY gained